Ahmad R Abuzinadah1,2, Mohammed H Alanazy3, Nadeem S Butt4, Richard J Barohn5, Mazen M Dimachkie5. 1. Internal Medicine Department, Neurology Division and Neuroscience Unit, King Abdulaziz University Hospital and Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, aabuzinadah@kau.edu.sa. 2. Neuromuscular Unit, King Abdulaziz University Hospital and King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia, aabuzinadah@kau.edu.sa. 3. Department of Internal Medicine, King Saud University Medical City and College of Medicine, King Saud University, Riyadh, Saudi Arabia. 4. Department of Family and Community Medicine, Faculty of Medicine In Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia. 5. Neurology Department, The University of Kansas Medical Center, Kansas City, Kansas, USA.
Abstract
OBJECTIVE: The aim of the study was to estimate the exacerbation incidence rate (IR) in acetylcholine receptor antibody (AChR)-positive generalized myasthenia gravis (MG) and its predictors. METHODS: The primary outcome in this retrospective study was to estimate moderate-to-severe (M-S) exacerbations IR in the early course of generalized MG. The secondary outcome was to explore the predictors of MG exacerbations. RESULTS: Between 1999 and 2015, we identified 78 AChR-positive generalized MG patients and 37 M-S exacerbations over the first 6 years following the onset of generalized MG symptoms. The M-S exacerbation IR was 12.2 per 100 person years (95% confidence interval [CI] 8.8-16.8). Any exacerbation (including mild) IR was 24.4 per 100 person years (95% CI 19.4-30.7). After controlling for confounding factors, MG exacerbation IR predictors included gender, disease severity at onset, and prednisone dose reduction with risk ratio of 0.34 (male gender), 2.67, and 20.8, respectively (all p values <0.05). M-S exacerbation occurred in 25 cases (32.1%), while any exacerbation (mild or M-S) was detected in 45 cases (57.7%). CONCLUSION: More than half of newly diagnosed AChR + MG cases experience an exacerbation in the first 6 years. Gender, disease severity at onset and prednisone dose reduction are predictors that could inform clinical practice and future research.
OBJECTIVE: The aim of the study was to estimate the exacerbation incidence rate (IR) in acetylcholine receptor antibody (AChR)-positive generalized myasthenia gravis (MG) and its predictors. METHODS: The primary outcome in this retrospective study was to estimate moderate-to-severe (M-S) exacerbations IR in the early course of generalized MG. The secondary outcome was to explore the predictors of MG exacerbations. RESULTS: Between 1999 and 2015, we identified 78 AChR-positive generalized MG patients and 37 M-S exacerbations over the first 6 years following the onset of generalized MG symptoms. The M-S exacerbation IR was 12.2 per 100 person years (95% confidence interval [CI] 8.8-16.8). Any exacerbation (including mild) IR was 24.4 per 100 person years (95% CI 19.4-30.7). After controlling for confounding factors, MG exacerbation IR predictors included gender, disease severity at onset, and prednisone dose reduction with risk ratio of 0.34 (male gender), 2.67, and 20.8, respectively (all p values <0.05). M-S exacerbation occurred in 25 cases (32.1%), while any exacerbation (mild or M-S) was detected in 45 cases (57.7%). CONCLUSION: More than half of newly diagnosed AChR + MG cases experience an exacerbation in the first 6 years. Gender, disease severity at onset and prednisone dose reduction are predictors that could inform clinical practice and future research.
Authors: E Beghi; C Antozzi; A P Batocchi; F Cornelio; V Cosi; A Evoli; M Lombardi; R Mantegazza; M L Monticelli; G Piccolo Journal: J Neurol Sci Date: 1991-12 Impact factor: 3.181
Authors: Ahmad R Abuzinadah; Duaa Jabari; Omar Jawdat; Mamatha Pasnoor; Melanie Glenn; Laura Herbelin; April L McVey; Richard J Barohn; Mazen M Dimachkie Journal: J Clin Neuromuscul Dis Date: 2018-12
Authors: Gil I Wolfe; Henry J Kaminski; Inmaculada B Aban; Greg Minisman; Hui-Chien Kuo; Alexander Marx; Philipp Ströbel; Claudio Mazia; Joel Oger; J Gabriel Cea; Jeannine M Heckmann; Amelia Evoli; Wilfred Nix; Emma Ciafaloni; Giovanni Antonini; Rawiphan Witoonpanich; John O King; Said R Beydoun; Colin H Chalk; Alexandru C Barboi; Anthony A Amato; Aziz I Shaibani; Bashar Katirji; Bryan R F Lecky; Camilla Buckley; Angela Vincent; Elza Dias-Tosta; Hiroaki Yoshikawa; Márcia Waddington-Cruz; Michael T Pulley; Michael H Rivner; Anna Kostera-Pruszczyk; Robert M Pascuzzi; Carlayne E Jackson; Guillermo S Garcia Ramos; Jan J G M Verschuuren; Janice M Massey; John T Kissel; Lineu C Werneck; Michael Benatar; Richard J Barohn; Rup Tandan; Tahseen Mozaffar; Robin Conwit; Joanne Odenkirchen; Joshua R Sonett; Alfred Jaretzki; John Newsom-Davis; Gary R Cutter Journal: N Engl J Med Date: 2016-08-11 Impact factor: 91.245
Authors: James F Howard; Kimiaki Utsugisawa; Michael Benatar; Hiroyuki Murai; Richard J Barohn; Isabel Illa; Saiju Jacob; John Vissing; Ted M Burns; John T Kissel; Srikanth Muppidi; Richard J Nowak; Fanny O'Brien; Jing-Jing Wang; Renato Mantegazza Journal: Lancet Neurol Date: 2017-10-20 Impact factor: 44.182
Authors: Donald B Sanders; Gil I Wolfe; Michael Benatar; Amelia Evoli; Nils E Gilhus; Isabel Illa; Nancy Kuntz; Janice M Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David P Richman; Jan Verschuuren; Pushpa Narayanaswami Journal: Neurology Date: 2016-06-29 Impact factor: 9.910
Authors: Karen Hewett; Donald B Sanders; Richard A Grove; Christine L Broderick; Todd J Rudo; Ashlyn Bassiri; Marina Zvartau-Hind; Vera Bril Journal: Neurology Date: 2018-03-21 Impact factor: 9.910
Authors: Malin Petersson; Amalia Feresiadou; Daniel Jons; Andreea Ilinca; Fredrik Lundin; Rune Johansson; Anna Budzianowska; Anna-Karin Roos; Viktor Kågström; Martin Gunnarsson; Peter Sundström; Fredrik Piehl; Susanna Brauner Journal: Neurology Date: 2021-08-10 Impact factor: 9.910